Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges.

@article{Alameddine2013CrosstalkBH,
  title={Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges.},
  author={Raafat S Alameddine and Zaher K. Otrock and Ahmad Hussein Awada and Ali Shamseddine},
  journal={Current opinion in oncology},
  year={2013},
  volume={25 3},
  pages={313-24}
}
PURPOSE OF REVIEW Angiogenesis is an essential hallmark of cancer. Targeting angiogenesis has proven its efficacy in the modern therapeutic paradigm. HER2 positive breast cancer, in particular, is a challenging disease in which resistance to standard therapy has been attributed to parallel and downstream signaling cascades including angiogenesis. This review explores the molecular mechanisms underlying crosstalk between HER2 signaling and angiogenesis. It highlights the role of angiogenesis in… CONTINUE READING
Highly Cited
This paper has 60 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

61 Citations

0102030'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 61 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 102 references

A randomized phase II study ( VEG 108838 ) of lapatanib plus pazopanib ( L þ P ) versus lapatanib ( L ) in patients with ErbB 2 þ inflammatory breast cancer ( IBC )

G Gasparini
ASCO Meeting Abstracts • 2012

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first - line therapy for HER 2positive metastatic breast cancer

M Cristofanilli, Johnston SRD, A Manikhas
Breast • 2012

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first - line treatment for HER2positive locally recurrent or metastatic breast cancer

J Gligorov
Oncologist • 2012

Primary results of BEATRICE , a randomized phase III trial evaluating adjuvant bevacizumabcontaining therapy in triplenegative breast cancer

JM Ebos, CR Lee, W Cruz-Munoz
Cancer Res • 2012

A phase II study of lapatinib and bevacizumab as treatment for HER 2overexpressing metastatic breast cancer

HS Rugo, A JoChien, SX Franco
Breast Cancer Res Treat • 2011

Cardiotoxicity in patients treated with bevacizumab is potentially reversible.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011

Similar Papers

Loading similar papers…